Physician profile
Mary Rigoni
NPI 1306247010
$1,025.38
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $287 · 2022: $459 · 2023: $183 · 2024: $96.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $279.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $174.15 | 2021-2024 | |
| Exeltis, USA INC. | $161.86 | 2021-2024 | Slynd |
| Mayne Pharma Commercial LLC | $161.63 | 2021-2023 | |
| Aspira Women'S Health INC | $126.85 | 2022 | |
| Agile Therapeutics, INC. | $85.51 | 2021-2022 | |
| Coopersurgical, INC. | $82.64 | 2021-2023 | Paragard T 380a |
| Exact Sciences Corporation | $45.68 | 2023 | Cologuard Collection Kit |
| Evofem Biosciences, INC. | $38.05 | 2021-2022 | |
| Therapeuticsmd, INC. | $37.78 | 2021-2022 | |
| Myovant Sciences INC. | $29.05 | 2022 | |
| Scynexis, INC. | $24.73 | 2022 | |
| Astellas Pharma US INC | $24.55 | 2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $20.96 | 2021 | |
| Avion Pharmaceuticals | $11.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Rigoni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.